

Group history


Not only “always putting patients first”
but also striving to succeed in
“always putting healthier lives first”
for all people



1929
Sawai Pharmacy, the predecessor of Sawai Pharmaceutical Co., Ltd., was founded in Asahi-ku, Osaka City.

1948
Sawai Pharmaceutical Co., Ltd. was incorporated in Asahi-ku, Osaka City.

1965
Shifted from making OTC drugs to ethical pharmaceuticals.



1929–
Sawai Pharmacy founded in Asahi-ku Osaka as local pharmacy

Sawai Pharmaceutical's history starts almost 90 years ago. Hanpei Sawai and Noyo Sawai (a pharmacist) established Sawai Pharmacy, Sawai Pharmaceutical's predecessor. At that time, there were few pharmacies, and Sawai Pharmacy supported the health of residents by providing drugs as a local pharmacy.

1965–
Transformed into manufacturer of prescription medications and then into a leading GE company

In response to changes in the drug market due to the introduction of a universal medical care insurance system, Sawai transformed itself from a manufacturer of over-the-counter medications into a manufacturer of prescription medications. By supplying one product after another that meet the needs of healthcare professionals, we have built a foundation to grow into a leading company in the generic drug industry.

2003–
Contributed to spreading and expanding GE as a company listed on the First Section of the Tokyo Stock Exchange

In line with the basic policies of expanding market share, further strengthening the management structure, and building a solid Sawai brand, Sawai continued to grow, boosted by the tail wind of government policies to promote the use of generic drugs. We also strengthened our production and development capabilities, which included construction of the Kanto and Sanda Nishi factories and a new development center.

2021–
Transformed into GE manufacturer that continues to be selected with an eye toward industry reorganization

Sawai transitioned to a holding company structure in 2021 in order to strengthen its existing businesses and foster new businesses that meet the needs of the time. In fiscal 2022, revenue exceeded ¥200.0 billion (including discontinued operations), as the Company worked to provide a stable supply of inexpensive, high-quality generic drug as social infrastructure.